The site of the Media Sphera Publishers contains materials intended solely for healthcare professionals.
By closing this message, you confirm that you are a certified medical professional or a student of a medical educational institution.

Login
EN
+7 (495) 482-4118
+7 (495) 482-4329
+8 800 250-18-12
  • (toll-free number for subscriptions)
    Mon-Fri from 10 a.m. to 6 p.m.

  • © 1998-2026
+7 (495) 482-43-29
EN
All journals
Journal
Year
Year
Search result: 0

Trifanov V.S.

P.A. Herzen Moscow Oncology Research Institute — Branch of the National Medical Radiology Research Center

Kopylov V.V.

P.A. Herzen Moscow Oncology Research Institute — Branch of the National Medical Radiology Research Center

Grishin N.A.

P.A. Herzen Moscow Oncology Research Institute — Branch of the National Medical Radiology Research Center

Volchenko N.N.

P.A. Herzen Moscow Oncology Research Institute — Branch of the National Medical Radiology Research Center

Malushkova M.E.

P.A. Herzen Moscow Oncology Research Institute — Branch of the National Medical Radiology Research Center

Troitsky A.A.

P.A. Herzen Moscow Oncology Research Institute — Branch of the National Medical Radiology Research Center

Moshurov R.I.

P.A. Herzen Moscow Oncology Research Institute — Branch of the National Medical Radiology Research Center

Poluektov S.I.

P.A. Herzen Moscow Oncology Research Institute — Branch of the National Medical Radiology Research Center

Kosogolov M.V.

P.A. Herzen Moscow Oncology Research Institute — Branch of the National Medical Radiology Research Center

Hepatocellular carcinoma associated with nonalcoholic fatty liver disease

Authors:

Trifanov V.S., Kopylov V.V., Grishin N.A., Volchenko N.N., Malushkova M.E., Troitsky A.A., Moshurov R.I., Poluektov S.I., Kosogolov M.V.

More about the authors

Journal: P.A. Herzen Journal of Oncology. 2024;13(6): 57‑62

DOI: 10.17116/onkolog20241306157

Read: 1234 times

Download PDF (RU)
Contact the author
Table of contents

HEPATOCELLULAR CARCINOMA ASSOCIATED WITH NONALCOHOLIC FATTY LIVER DISEASE
HEPATOCELLULAR CARCINOMA ASSOCIATED WITH NONALCOHOLIC FATTY LIVER DISEASE

To cite this article:

Trifanov VS, Kopylov VV, Grishin NA, et al. . Hepatocellular carcinoma associated with nonalcoholic fatty liver disease. P.A. Herzen Journal of Oncology. 2024;13(6):57‑62. (In Russ.)
https://doi.org/10.17116/onkolog20241306157

Подписка 2026 Онкология. Журнал им. П.А. Герцена (P.A. Herzen Journal of Oncology)
МСФ на ЯМ
Использование инфографики авторами научных работ
Close metadata
Recommended articles:
The condition of bone tissue in patients with non-alcoholic fatty liver disease. Russian Journal of Preventive Medi­cine. 2025;(5):82-89
Evaluation of periodontal status in patients with liver cirrhosis. Stomatology. 2025;(2):6-10
Effe­ctiveness of etiotropic therapy in achieving reco­mpensation of cirrhosis. Russian Journal of Evidence-Based Gastroenterology. 2025;(2):68-77
Sarcopenia index for dete­cting of the decreased muscle stre­ngth and mass in patients with the non-alcoholic fatty liver disease. Russian Journal of Preventive Medi­cine. 2025;(7):68-74
Non-alcoholic fatty liver disease: a view formation on the problem and its significance for the clinical practice. Russian Journal of Preventive Medi­cine. 2025;(7):127-132
Combination of urso­deoxycholic acid and glycyrrhizic acid (Phosphogliv URSO) in the treatment of nona­lcoholic fatty liver disease: resu­lts of a multicenter randomized clinical trial on effi­cacy and safety. Russian Journal of Evidence-Based Gastroenterology. 2025;(3):71-84
Pharmacotherapy of the meta­bolically asso­ciated fatty liver disease. Russian Journal of Preventive Medi­cine. 2025;(10):103-108
The effi­cacy of hepa­toprotective agents in the treatment of non-alcoholic fatty liver disease: meta­bolic effe­cts and impact on liver fat content. Russian Journal of Preventive Medi­cine. 2026;(1):86-93
Abstract:

The clinical observation is devoted to the successful surgical treatment of a patient with primary liver cancer that developed against the background of non-alcoholic fatty liver disease. This pathology as a predictor of hepatocellular carcinoma has recently come out on top in frequency, displacing hepatitis and cirrhosis of viral etiology. The literature review provides data on the incidence of steatosis and steatohepatitis in developed countries of the world, as well as mechanisms of hepatocarcinogenesis against the background of these conditions, morphological characteristics of these subtypes of liver carcinoma, and diagnostic difficulties.

Keywords:

hepatocellular carcinoma
steatohepatitis
nonalcoholic fatty liver disease
liver cirrhosis
viral hepatitis
nonalcoholic steatohepatitis subtype of hepatocellular carcinoma

Authors:

Trifanov V.S.

P.A. Herzen Moscow Oncology Research Institute — Branch of the National Medical Radiology Research Center

Kopylov V.V.

P.A. Herzen Moscow Oncology Research Institute — Branch of the National Medical Radiology Research Center

Grishin N.A.

P.A. Herzen Moscow Oncology Research Institute — Branch of the National Medical Radiology Research Center

Volchenko N.N.

P.A. Herzen Moscow Oncology Research Institute — Branch of the National Medical Radiology Research Center

Malushkova M.E.

P.A. Herzen Moscow Oncology Research Institute — Branch of the National Medical Radiology Research Center

Troitsky A.A.

P.A. Herzen Moscow Oncology Research Institute — Branch of the National Medical Radiology Research Center

Moshurov R.I.

P.A. Herzen Moscow Oncology Research Institute — Branch of the National Medical Radiology Research Center

Poluektov S.I.

P.A. Herzen Moscow Oncology Research Institute — Branch of the National Medical Radiology Research Center

Kosogolov M.V.

P.A. Herzen Moscow Oncology Research Institute — Branch of the National Medical Radiology Research Center

Received:

22.01.2024

Accepted:

26.02.2024

Close metadata

References:

  1. Agni RM. Diagnostic histopathology of hepatocellular carcinoma: a case-based review. Semin Diagn Pathol. 2017;34(2):126-137.  https://doi.org/10.1053/j.semdp.2016.12.008
  2. Marengo A, Rosso C, Bugianesi E. Liver cancer: connections with obesity, fatty liver, and cirrhosis. Annu Rev Med. 2016;67:103-117.  https://doi.org/10.1146/annurev-med-090514-013832
  3. Chalasani N, Younossi Z, Lavine JE, Charlton M, Cusi K, Rinella M, Harrison SA, Brunt EM, Sanyal AJ. The diagnosis and management of nonalcoholic fatty liver disease: practice guidance from the American Association for the Study of Liver Diseases. Hepatology. 2018;67(1):328-357.  https://doi.org/10.1002/hep.29367
  4. Tovo CV, de Mattos AZ, Coral GP, Sartori GDP, Nogueira LV, Both GT, Villela-Nogueira CA, de Mattos AA. Hepatocellular carcinoma in non-alcoholic steatohepatitis without cirrhosis. World J Gastroenterol. 2023;29(2):343-356.  https://doi.org/10.3748/wjg.v29.i2.343
  5. Kaprin AD, Starinskii VV, Shakhzadova AO, eds. Zlokachestvennye novoobrazovaniya v Rossii v 2019 g. (zabolevaemost’ i smertnost’). Moscow: MNIOI im. P.A. Gertsena — filial FGBU «NMITs radiologii» Minzdrava Rossii; 2020. 252p. (In Russian).
  6. Tiniakos DG, Maurício J, Reeves HL. Fatty liver disease and hepatocellular carcinoma: the pathologist’s view. Adv Exp Med Biol. 2018;1032:55-69.  https://doi.org/10.1007/978-3-319-98788-0_4
  7. Grinevich VB, Kravchuk YuA, Ped’ VI, Arapkhanova MM, Sheraliev AR. Carcinogenesis in patients with non-alcoholic fatty liver disease without cirrhosis: the role of bile acids and intestinal microbiota. Experimental and Clinical Gastroenterology. 2019;(8):4-10. (In Russian). https://doi.org/10.31146/1682-8658-ecg-168-8-4-10
  8. Chen K, Xu Y, Dong Y, Han H, Mao F, Wang H, Song X, Luo R, Wang WP. Contrast-enhanced imaging features and clinicopathological investigation of steatohepatitic hepatocellular carcinoma. Diagnostics (Basel). 2023;13(7):1337. https://doi.org/10.3390/diagnostics13071337
  9. Zvenigorodskaya LA, Shinkin MV. Non-alcoholic fatty liver disease and diabetes mellitus: targets of metabolic tandem. Consilium Medicum. 2017;19(4):50-57. (In Russian).
  10. Takahashi Y, Fukusato T. Histopathology of nonalcoholic fatty liver disease/nonalcoholic steatohepatitis. World J Gastroenterol. 2014;20(42):15539-15548. https://doi.org/10.3748/wjg.v20.i42.15539
  11. Van Treeck BJ, Mounajjed T, Moreira RK, Orujov M, Allende DS, Bellizzi AM, Lagana SM, Davila JI, Jessen E, Graham RP. Transcriptomic and proteomic analysis of steatohepatitic hepatocellular carcinoma reveals novel distinct biologic features. Am J Clin Pathol. 2021;155(1):87-96.  https://doi.org/10.1093/ajcp/aqaa114
  12. Deniz K, Moreira RK, Yeh MM, Ferrell LD. Steatohepatitis-like changes in focal nodular hyperplasia, a finding to distinguish from steatohepatitic variant of hepatocellular carcinoma. Am J Surg Pathol. 2017;41(2):277-281.  https://doi.org/10.1097/PAS.0000000000000781
  13. Vij M, Calderaro J. Pathologic and molecular features of hepatocellular carcinoma: an update. World J Hepatol. 2021;13(4):393-410.  https://doi.org/10.4254/wjh.v13.i4.393
  14. Olofson AM, Gonzalo DH, Chang M, Liu X. Steatohepatitic variant of hepatocellular carcinoma: a focused review. Gastroenterol Res. 2018;11(6):391-396.  https://doi.org/10.14740/gr1110
  15. Pavlenko OA. Ozhirenie kak faktor riska nealkogol’noi zhirovoi bolezni pecheni. Al’manakh Klinicheskoi Meditsiny. 2015;(Special Issue 1):60-66. (In Russian).
  16. Bogolyubova AV, Maiorov AYu, Mishina EE, Shwarts AM, Belousov PV. Farnesoid X receptor (FXR) as a potential therapeutic target in nonalcoholic fatty liver disease and associated syndromes. Diabetes Mellitus. 2017;20(6):449-453. (In Russian). https://doi.org/10.14341/DM9374
  17. Tsukanov VV, Yurkina AS, Ushakova TA, Blinov DV. Epidemiologicheskie osobennosti nealkogol’noi zhirovoi bolezni pecheni v Novosibirske (Sibirskii federal’nyi okrug): regional’nye dannye otkrytogo mnogotsentrovogo prospektivnogo issledovaniya DIREG 2. Farmakoekonomika. Sovremennaya farmakoekonomika i farmakoepidemiologiya. 2016;9(2):17-27. (In Russian). https://doi.org/10.17749/2070-4909.2016.9.2.017-027
  18. Loy LM, Low HM, Choi JY, Rhee H, Wong CF, Tan CH. Variant hepatocellular carcinoma subtypes according to the 2019 WHO Classification: an imaging-focused review. AJR Am J Roentgenol. 2022;219(2):212-223.  https://doi.org/10.2214/AJR.21.26982
  19. Yoon JK, Choi JY, Rhee H, Park YN. MRI features of histologic subtypes of hepatocellular carcinoma: correlation with histologic, genetic, and molecular biologic classification. Eur Radiol. 2022;32(8):5119-5133. https://doi.org/10.1007/s00330-022-08643-4
  20. Salomao M, Yu WM, Brown RS Jr, Emond JC, Lefkowitch JH. Steatohepatitic hepatocellular carcinoma (SH-HCC): a distinctive histological variant of HCC in hepatitis C virus-related cirrhosis with associated NAFLD/NASH. Am J Surg Pathol. 2010;34(11):1630-1636. https://doi.org/10.1097/PAS.0b013e3181f31caa
  21. Jain D, Nayak NC, Kumaran V, Saigal S. Steatohepatitic hepatocellular carcinoma, a morphologic indicator of associated metabolic risk factors: a study from India. Arch Pathol Lab Med. 2013;137(7):961-966.  https://doi.org/10.5858/arpa.2012-0048-OA
  22. Cannella R, Dioguardi Burgio M, Beaufrère A, Trapani L, Paradis V, Hobeika C, Cauchy F, Bouattour M, Vilgrain V, Sartoris R, et al. Imaging features of histological subtypes of hepatocellular carcinoma: implication for LI-RADS. JHEP Rep. 20213;3(6):100380. https://doi.org/10.1016/j.jhepr.2021.100380
  23. Hu YX, Shen JX, Han J, Mao SY, Mao RS, Li Q, Li F, Guo ZX, Zhou JH. Diagnosis of non-hepatocellular carcinoma malignancies in patients with risks for hepatocellular carcinoma: CEUS LI-RADS Versus CT/MRI LI-RADS. Front Oncol. 2021:11:641195. https://doi.org/10.3389/fonc.2021.641195
  24. Katabathina VS, Khanna L, Surabhi VR, Minervini M, Shanbhogue K, Dasyam AK, Prasad SR. Morphomolecular classification update on hepatocellular adenoma, hepatocellular carcinoma, and intrahepatic cholangiocarcinoma. Radiographics. 2022;42(5):1338-1357. https://doi.org/10.1148/rg.210206
Contact the author
Email
Message
The publishing house "Media Sphere" does not provide treatment services, does not give recommendations on contacting medical institutions and specific specialists, on the prescription of medicines and dietary supplements.

Email Confirmation

An email was sent to test@gmail.com with a confirmation link. Follow the link from the letter to complete the registration on the site.

Email Confirmation

Contact us
If you have any questions, complaints or suggestions, please use this feedback form.
Email
Message
The publishing house "Media Sphere" does not provide treatment services, does not give recommendations on contacting medical institutions and specific specialists, on the prescription of medicines and dietary supplements.
Submit Application

You can become an author of one of our magazines, send a request and we will consider it in during the day.

Name
Phone
E-mail
Message
Login
Registration
E-mail
Password
Forgot Password?

Log in to the site using your account in one of the services

Password recovery
E-mail
Login
Register

We use cооkies to improve the performance of the site. By staying on our site, you agree to the terms of use of cооkies. To view our Privacy and Cookie Policy, please. click here.